Legend Biotech USA presented early clinical evidence for LB-2501, an off-the-shelf CD19/CD20 dual-targeting CAR T cell program, aiming to enable outpatient use. At EHA2026, investigators reported that all six patients treated at the higher dose responded, including five complete responses, with responses deepening in some cases over time. Safety outcomes to date were a key focus: while adverse events increased from dose level one to two, the highest grade reported so far was grade two, and there was no neurotoxicity. Legend’s leadership framed the tolerability as a notable point compared with autologous CAR T experiences, where higher-grade adverse events are more common. The presentation also referenced context from Kelonia Therapeutics’ KLN-1010 BCMA CAR T program in multiple myeloma, where updated data were described as showing deep responses and no detectable MRD in available cases a month after treatment.